AstraZeneca Plc expects revenue to increase by a low-to-mid single-digit percentage this year on the strength of its oncology portfolio and a continued penetration of the emerging markets. Revenue for the first quarter was $10.9 billion, unchanged from a year earlier at constant exchange rates, and down by 4% on a reported basis. While the US remains the company’s most important market, with sales of $4.3 billion in the quarter, the emerging markets including China were second, contributing $3.2 billion. China alone generated $1.6 billion or 15% of total group revenue.
